On the HCPLive Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.
May 13th 2024
At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.
In Patients with Wet AMD, Cataract Surgery Shown Not to Increase Need for Anti-VEGF Injections
A Danish electronic records review found that the need for Eylea or Lucentis injections for wet age-related macular degeneration did not change after cataract surgery. Also, vision improved more when the time from last injection to cataract surgery was shorter than when it was longer.
Patients in the open-label extension phase of RIDE/RISE who needed Lucentis less frequently tended to have less advanced diabetic macular edema (DME) at extension baseline and to respond better to initial treatment, according to post hoc analysis. These results suggest that earlier treatment of center-involving DME with loss of visual acuity may decrease its long-term treatment burden.
The rate of endophthalmitis after more than 90,000 intravitreal injections was found to be approximately 1 in 3000 in a retrospective study of a consecutive series of cases at a multicenter, retina-only practice. Prophylactic use of topical antibiotics was not found to decrease this rate.
Assessing Rates of Noninfectious Vitritis after Intravitreal Injection of Anti-VEGF Agents
Although intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has become the therapeutic mainstay for diabetic macular edema and neovascular age-related macular degeneration, it poses a risk of noninfectious uveitis or infectious endopthalmitis.
A retrospective chart review study showed that the location of subfoveal fibrovascular scarring in relation to the retinal pigment epithelium correlated with visual outcome in eyes successfully treated with anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Oral Bisphosphonate Use Poses Risk of Wet Age-Related Macular Degeneration
Regular users of oral bisphosphonates had a higher risk of developing wet age-related macular degeneration than non-users, according to results of a recent Canadian study, and the longer the use, the greater the increased risk.
Intraocular injections of methotrexate have been used successfully to treat indeterminate and sarcoid uveitis as well as age-related macular degeneration. Methotrexate injection’s record of success in treating these inflammatory eye diseases prompted researchers to evaluate its efficacy in treating persistent diabetic macular edema.
Patients with neovascular age-related macular degeneration have shown a suboptimal response to ranibizumab over time. Several studies have established that switching from ranibizumab to aflibercept enhanced visual acuity and resulted in anatomic improvement in many of these patients, but the factors determining visual outcomes remained unclear.
Combination Treatment with Ranibizumab and AKB-9778 Shows Promise in Diabetic Macular Edema
Study results show that patients with diabetic macular edema are more likely to improve with treatment by a combination of ranibizumab and AKB-9778, as compared to treatment with either alone.
Teriflunomide Shows Efficacy in Multiple Sclerosis with Optic Neuritis Subtype
June 1st 2016A phase III study that examined teriflunomide (Aubagio) in a subtype of patients with multiple sclerosis was presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.
Pinakin Davey from the Western University of Health Sciences: Improving imaging in Ophthalmology
Even a decade ago the technology used in diagnosis for ophthalmology was still developing. In that time work has been done to improve the ways doctors can see the potential problems their patients may have to provide a higher level of care.
Randy Kardon: Improving Technology to Help Diagnosis Process
A condition like chronic traumatic encephalopathy is only able to be diagnosed now after a patient has already died. New technology is being developed to help patients while they are still alive. These new techniques could also be used to help other conditions as well.
Online Eye Exam Site Shakes Up Vision Healthcare
It can sometimes seem like there truly is an app for everything these days. From tools that monitor how many steps the user takes each day to applications that assess sleep patterns, physicians and patients have a wide array of choices that can help them maintain good health.